3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
17
Glioblastoma
8
Esophageal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Rectal Neoplasms
7
Oropharyngeal Neoplasms
7
Breast Neoplasms
7
Mouth Neoplasms
6
Glioma
6
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Laryngeal Neoplasms
4
Head and Neck Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Sarcoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Neuroblastoma
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Medulloblastoma
2
Hypopharyngeal Neoplasms
2
Ganglioneuroblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
venetoclax
27
fludarabine
26
Cyclophosphamide
25
Specimen Handling
21
Azacitidine
20
Biopsy
15
Whole-Body Irradiation
14
Stem Cell Transplantation
13
Decitabine
13
Cytarabine
13
Tacrolimus
12
Melphalan
12
fludarabine phosphate
11
Mycophenolic Acid
11
Busulfan
11
Injections
8
X-Rays
7
Thiotepa
7
Hematopoietic Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
decitabine and cedazuridine drug combination
6
Cyclosporine
6
ruxolitinib
5
Magnetic Resonance Spectroscopy
5
Idarubicin
5
Filgrastim
5
gilteritinib
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myelodysplastic Syndromes
×
Radiation
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled